Tumor cells usually secrete soluble factors to improve their proliferation via autocrine network or to escape from immune surveillance by inhibiting antitumor immunity, among these factors IL-10 and IL-6 play more important roles. Since both cytokines signal transductions are mediated through the STAT3 pathway, STAT3 becomes an attractive target for tumor therapy. In present study, STAT3 of murine tumor cell lines B16 and MCA-38 was constitutively activated. After treatment with STAT3-decoy ODN, the proliferation of these tumor cells was inhibited and the transcription of IL-10 or IL-6 in tumor cells was down-regulated. These results suggested that STAT3 is a good target candidate, and STAT3-decoy ODN may possibly be used as a strategy for breaking both tumor autocrine network and tumor immunotolerance.